Disclosure Slide. Controversies in Anticoagulation. Presenter Disclosure Information. Challenges in Anticoagulation
|
|
- Allan Arnold
- 5 years ago
- Views:
Transcription
1 1:15 2:15 PM Challenges in Anticoagulation SPEAKER Nasser Lakkis, MD, FACC, FSCAI Presenter Disclosure Information The following relationships exist related to this presentation: Nasser Lakkis, MD, FACC, FSCAI: No financial relationships to disclose. Off-Label/Investigational Discussion In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Disclosure Slide Controversies in Anticoagulation Dr. Nasser Lakkis has reported no interest or other relationship(s) with commercial interests (drug/device companies) that may relate to the educational content of this activity Nasser Lakkis, MD Professor of Medicine Baylor College of Medicine
2 Learning Objectives Atherothrombosis 1. review mechanism of action of antiplatelet and anticoagulant agents 2. Review evidence for indications and efficacy of anticoagulants 3. Discuss combined use of antiplatelet and antithrombin agents 4. Management of anticoagulants in patients requiring invasive procedures Modified from the REACH Registry Investigators. JAMA 26;295(2): Antithrombin Drug Targets Aspirin for Primary Prevention Antithrombotic Trialists (ATT) Collaboration Non fatal MI Any stroke Vascular Mortality Rate Ratios for Vascular Events P value P<.1 P=.4 P=.7 Major extracranial bleed P<.1 Serious Vascular Events P= Antiplatelet Better Antiplatelet Worse Aspirin reduces the risk of MI and vascular events at the expense of bleeding Lancet 29;373:
3 Aspirin for Secondary Prevention Effect of antiplatelet treatment* on vascular events** Category Acute MI Acute CVA Prior MI Prior CVA/TIA Other high risk CVD (e.g. unstable angina, heart failure) PAD (e.g. intermittent claudication) High risk of embolism (e.g. Afib) Other (e.g. DM) All trials % Odds Reduction Antiplatelet better Control better Aspirin reduces the risk of adverse cardiovascular events Clopidogrel for Secondary Prevention Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) Trial 19,185 patients with ischemic CVA, MI, or PAD randomized to daily aspirin (325 mg) or clopidogrel (75 mg) for 2 years Cumulative risk* (%) Months of follow-up Aspirin Clopidogrel 8.7% RRR, p=.43 Clopidogrel provides slightly greater risk reduction than aspirin. BMJ 22;324:71 86 Lancet 1996;348: Clopidogrel for Secondary Prevention Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial 12,562 patients with a NSTE ACS randomized to daily aspirin ( mg) or clopidogrel (3 mg load, 75 mg thereafter) plus aspirin ( mg) for 9 months Rate of CV death, myocardial infarction, or stroke Aspirin + Placebo Aspirin + Clopidogrel P< Months of Follow Up Dual antiplatelet therapy is more efficacious in a NSTE ACS Clopidogrel for Secondary Prevention Clopidogrel for the Reduction of Events during Observation (CREDO) Trial 2,116 patients undergoing PCI randomized to 4 weeks of DAPT* followed by aspirin ( mg) monotherapy vs. persistent DAPT* for 1 year Risk of MI, stroke, or death (%) 15 4 weeks of DAPT* Months from Randomization 1 year of DAPT* 27% RRR, P=.2 DAPT produces greater benefit when used for 1 year 12. NEJM 21;345: JAMA 22;288:
4 Death, MI, or Stroke, % Clopidogrel for Secondary Prevention Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) 45,852 patients presenting within 24 hours of a STEMI treated medically and randomized to clopidogrel (75 mg daily) vs. placebo 1 (1.1%) (9.2%) 8 (8.1%) (7.5%) % relative risk reduction (P=.2) 1 7% relative risk reduction (P=.3) Days Since Randomization (up to 28 days) Days Since Randomization (up to 28 days) DAPT produces greater benefit in medically managed STEMI patients In-Hospital Mortality, % Clopidogrel for Secondary Prevention Clopidogrel as Adjunctive Reperfusion Therapy in Thrombolysis in Myocardial Infarction (CLARITY) Trial 3,491 patients (<75 years of age) presenting within 12 hours of a STEMI treated with fibrinolytic, aspirin, and heparin and randomized to clopidogrel (3 mg load followed by 75 mg daily) vs. placebo End Point (%)* % RRR Aspirin + Clopidogrel Aspirin + Placebo P= Days DAPT benefits STEMI patients treated with fibrinolytic therapy Lancet 25;366: NEJM 25; 352: Clopidogrel for Secondary Prevention Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial 15,63 patients with multiple CV risk factors or known CVD randomized to aspirin ( mg) or aspirin ( mg) & clopidogrel (75 mg) for a mean of 3 months Incidence of CV death, MI, or CVA (%) Placebo Clopidogrel P = Months Routine DAP therapy offers little long term benefit Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events (CURRENT) OASIS 7 Trial CV death, MI, or stroke 25,87 patients with an ACS randomized in a 2 x 2 factorial trial to double dose clopidogrel (6 mg LD, 15 mg x 7 days, then 75 mg MD) vs. standard dose clopidogrel (3 mg LD and 75 mg MD) and high dose aspirin (3 325 mg) vs. low dose aspirin (75 1 mg)..2.4 Clopidogrel Secondary Prevention Clopidogrel Standard Clopidogrel Double HR.95, P= Days Type of Bleeding High dose clopidogrel does not provide benefit in ACS D (%) S (%) TIMI Major CURRENT Major* Fatal ICH.3.5 CABGrelated 1..9 *p=.1 NEJM 26;354: NEJM 21;363:93-942
5 Prasugrel for Secondary Prevention Primary Efficacy Endpoint and TIMI Major Bleeding Through 3 Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel (TRITON-TIMI 38) 13,68 patients with high-risk ACS scheduled for PCI randomized to clopidogrel (3 mg LD and 75 mg MD) or prasugrel (6 mg LD and 1 mg MD) for a median of 12 months Months (TRITON TIMI 38) (Age < 75 years, N = 7243) CV death, MI, or stroke % 12.1 HR.81, P=.4 11 Clopidogrel 9.9 Bleeding Events 9 C (%) P (%) P-value Prasugrel TIMI major Life threatening Nonfatal HR.77 HR.8 Fatal P=.1 P=.1 ICH Days Endpoint (%) HR (95% CI):.91 (.79, 1.5) P =.21 HR (95% CI): 1.31 (.81, 2.11) P =.27 Prasugrel reduces ischemic events with a higher rate of bleeding NEJM 27;357: Roe MT NEJM 212 Platelet Inhibition and Patient Outcomes (PLATO) Study 18,624 patients with a moderate to high risk ACS randomized to clopidogrel (3 6 mg LD and 75 mg MD) or ticagrelor (18 mg LD and 9 mg twice daily MD) for 12 months CV Death, MI, or Stroke (%) PLATO: Ticagrelor Secondary Prevention Clopidogrel Ticagrelor Days after randomization 11.7 HR.84, p= Bleeding Events * C (%) T (%) TIMI major/year PLATO major/year Life threatening/year Fatal/year.3.3 Ticagrelor reduces ischemic events with no higher rate of bleeding overall *No statistically significant differences were observed in bleeding rates overall NEJM 29;361: CV Death, MI, or Stroke (%) PEGASUS TIMI 54: Primary Endpoint 21,162 patients with MI 1 3 years prior and treated with low dose aspirin Months from Randomization Ticagrelor 9 mg HR.85 (95% CI.75.96) P=.8 Ticagrelor 6 mg HR.84 (95% CI.74.95) P= Placebo (9.%) Ticagrelor 9 (7.8%) Ticagrelor 6 (7.8%) NEJM 215;372:1791-8
6 PEGASUS TIMI 54: Adverse Events Leading to Discontinuation Number of Patients Year KM Rate (%) p value for each dose vs. placebo <.1 Treatment Arm Any AE Bleeding Dyspnea Ticagrelor 9 19.% 7.8% 6.5% Ticagrelor % 6.2% 4.6% Placebo 8.9% 1.5%.8% Placebo Ticagrelor 9 mg Ticagrelor 6 mg BID BID NEJM 215;372: Other Arrhythmia Dyspnea Bleeding P=NS each for D/C for arrhythmia or other Euclid: Ticagrelor in PAD N Engl J Med 217; 376:32 4 EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 9 mg twice daily (n = 6,93) vs. clopidogrel 75 mg daily (n = 6,955). % (p =.65) Results CV death, MI, or ischemic stroke: 1.8% of the ticagrelor group vs. 1.6% of the clopidogrel group (p =.65) Acute limb ischemia: 1.7% with ticagrelor vs. 1.7% with clopidogrel Major bleeding: 1.6% with ticagrelor vs. 1.6% with clopidogrel Dyspnea resulting in drug discontinuation: 4.8% with ticagrelor vs..8% with clopidogrel (p <.1) Conclusions Among patients with symptomatic PAD, ticagrelor was not superior to clopidogrel in preventing major adverse cardiac events Ticagrelor Clopidogrel Acute limb ischemia and major bleeding were also similar between treatment groups N Engl J Med 217;376:32-4 TRILOGY
7 Indications of Anticoagulant Therapy Treatment and Prevention of Deep Venous Thrombosis Treatment of Pulmonary Emboli Prevention and treatment of stroke in patients with atrial fibrillation, artificial heart valves, cardiac thrombus. Ischemic heart disease Drug/Trial Efficacy: Stroke/ Thromboembolism Hemorrhagic Stroke Major Bleeding Dabigatran in RE-LY 34% reduction 74% reduction Similar Rivaroxaban in ROCKET Apixaban in ARISOTLE Edoxaban ENGAGE AF TIMI48 Major Results of Trials Comparing NOACs to Warfarin in AF Noninferior to warfarin 4% reduction Similar 2% reduction 5% reduction 3% reduction Noninferior to warfarin 46% reduction 2% reduction N Engl J Med 213;369: Stroke. 214;45: NOACs in DVT/PE: EINSTEIN DVT (Rivaroxaban vs. Warfarin) Comparative Effectiveness of Warfarin and NOACs for long term prevention of arterial and thromboembolism N Engl J Med 21; 363: JAMA 215;:314: 76 7.
8 Summary of NOACs vs. Warfarin Non inferior for prevention of stroke/embolism in Afib Non inferior for treatment of DVT/PE Probable reduced hemorrhagic stroke rate Reduced rate of fatal bleeding events Increased incidence of GI bleeds Cost issues JAMA 215;:314: Drug Class Mechanis m of Action Indication Warfarin (Coumadin ) Anticoagulant (vitamin K antagonist) Depletes vitamin K inhibiting factors II, VII, IX, X DVT/PE/AF: INR (mechanical mitral valve) Dabigatran (Pradaxa ) Anticoagulant (direct thrombin inhibitor) Reversible direct thrombin inhibitor (PRODRUG) DVT/PE/NVAF: 15 mg BID (CrCl > 3 ml/min) 75 mg twice daily PO (CrCl 15-3 ml/min) Not recommended in CrCl < 15 ml/min Rivaroxaban (Xarelto ) Anticoagulant (factor Xa inhibitor) Selective inhibition of factor Xa Apixaban (Eliquis ) Anticoagulant (factor Xa inhibitor) Selective inhibition of factor Xa DVT/PE: DVT/PE: 15 mg BID with food for 3 weeks followed by 2 mg once daily Orthopedic prophylaxis: 1 mg once daily Nonvalvular atrial fibrillation*: 2 mg once daily with food PO; 15 mg once daily for CrCl 15-5 ml/min 1 mg BID followed by 5 mg BID for 6 months Nonvalvular atrial fibrillation: 5 mg twice daily PO; 2.5 mg BID if >2 of the following: 8 yo, 6kg, Cr 1.5 mg/dl Edoxaban (Savaysa ) Anticoagulant (factor Xa inhibitor) Selective inhibition of factor Xa DVT/PE/NVAF: 6 mg/d 3 mg/d: patients with CrCl 3-5 ml/min, weight 6 kg, or concomitant use of PgP inhibitors NOACs in CAD: COMPASS Trial COMPASS Primary: CV death, stroke, MI Stable CAD or PAD 2,2 with a primary outcome event Rivaroxaban 2.5 mg bid + aspirin 1 mg od Run-in (aspirin) R Rivaroxaban 5 mg bid Aspirin 1 mg od follow up 3-4 years N Engl J Med 217; 377: N Engl J Med 217; 377:
9 Outcome Major bleeding Fatal Non fatal ICH* Non fatal other critical organ* *symptomatic R + A N=9,152 COMPASS: Major bleeding R N=9,117 A N=9,126 Rivaroxaban + Aspirin vs. Aspirin N (%) N (%) N (%) HR (95% CI) P 3.1% 2.8% 1.9% 1.7 ( ) <.1.2%.2%.1% 1.49 ( ).32.2%.4%.2% 1.1 ( ).77.5%.5%.3% 1.43 ( ).14 Rivaroxaban vs. Aspirin HR (95% P CI) 1.51 ( ) < ( ) ( ) 1.57 ( ).6 Placebo N=5,176 ASA + Thieno, n=4,821 ASA, n=355 Recent ACS: STEMI, NSTEMI, UA No increased bleeding risk, No warfarin, No ICH, No prior stroke if on ASA + Thienopyridine Stabilized 1 7 Days Post Index Event Stratified by Thienopyridine use at MD Discretion RIVAROXABAN 2.5 mg BID n=5,174 ASA + Thieno, n=4,825 ASA, n=349 PRIMARY ENDPOINT: EFFICACY: CV Death, MI, Stroke* (Ischemic + Hemo) SAFETY: TIMI major bleeding not associated with CABG Event driven trial of 1,2 events in 15,342 patients** + ASA 75 to 1 mg/day RIVAROXABAN 5. mg BID N=5,176 ASA + Thieno, n=4,827 ASA, n=349 N Engl J Med 217; 377: N Engl J Med. 212;366:9 19 Primary Efficacy Endpoint CV Death / MI / Stroke* (Ischemic + Hemg.) Serious Bleeding Complications Estimated Cumulative Rate (%) No. at Risk Placebo Rivaroxaban Months After Randomization Placebo Rivaroxaban (both doses) % 8.9% HR.84 (.74.96) ARR 1.7% mitt p =.8 ITT p =.2 NNT = 59 p=ns for Riva vs Placebo p=.44 for 2.5 mg vs 5. mg * n=9 n=6 n=15 p=.9 Riva Vs Placebo n=5 n=14 n=18 p=ns for Riva vs Placebo n=4 n=5 n=8 N Engl J Med 212; 366:9 19 N Engl J Med 212; 366:9 19
10 21 patients with NVAF Coronary stenting No prior stroke/tia, No GI bleeding, Hb<1, CrCl<3 Patients With Atrial Fibrillation Undergoing Coronary Stent Placement: PIONEER AF PCI 72 hours After Sheath removal R A N D O M I Z E 1,6, or 12 months Pre randomization MD Choice Rivaroxaban 2.5 mg bid Clopidogrel 75 mg qd Aspirin 75 1 mg qd 1,6, or 12 months Pre randomization MD Choice VKA (target INR 2. 3.) Clopidogrel 75 mg qd Aspirin 75 1 mg qd Rivaroxaban 15 mg qd* Clopidogrel 75 mg qd Rivaroxaban 15mg QD Aspirin 75 1 mg qd VKA (target INR 2. 3.) Aspirin 75 1 mg qd Primary endpoint: TIMI major + minor + bleeding requiring medical attention Secondary endpoint: CV death, MI, and stroke (Ischemic, Hemorrhagic, or Uncertain Origin) End of treatment 12 months WOEST Like ATLAS Like Triple Therapy TIMI Major, TIMI Minor, or Bleeding Requiring Medical Attention (%) No. at risk Riva + P2Y 12 Riva + DAPT VKA + DAPT Kaplan Meier Estimates of First Occurrence of Clinically Significant Bleeding Events Days 26.7% p<.13 p< % VKA VKA + DAPT + DAPT 16.8% Riva + DAPT Riva + P2Y 12 HR =.63 (95% CI.5-.8) HR ARR =.59 = (95% 8.7 Riva + P2Y 12 v. VKA + DAPT CI ) Riva + DAPT v. VKA + DAPT ARR NNT = 9.9 = 12 HR=.59 (95% CI: ) HR=.63 (95% CI:.5-.8) p <.13 NNT = 11 p <.18 RR=9.9 RR=8.7 NNT=11 NNT= * Gibson et al. AHA 216 Gibson et al. AHA 216 Kaplan Meier Estimates of First Occurrence of CV Death, MI or Stroke Cardiovascular Death, Myocardial Infarction, or Stroke (%) VKA + DAPT Riva + P2Y 12 Riva + DAPT 6.5% 6.% 5.6% Riva + P2Y 12 v. VKA + DAPT HR=1.8 (95% CI: ) p=.75 Riva + DAPT v. VKA + DAPT HR=.93 (95% CI: ) p=.765 No. at risk Riva + P2Y 12 Riva + DAPT VKA + DAPT Days Gibson et al. AHA 216
11 APPRAISE 2: Primary Outcome CV Death, MI, Ischemic Stroke in ACS patients Apixaban 5 mg bid 279 (7.5%) Placebo 293 (7.9%) HR.95; 95% CI ; p=.59
12 APPRAISE 2: TIMI Major Bleeding Apixaban 48 (1.3%) Placebo 18 (.5%) HR 2.59; 95% CI ; p=.1 Triple Therapy Circulation 21;121:267 7 Lancet 213;381: Eur Heart J 216;37: To hold or not to hold for Procedures Delays procedure Longer in-hospital stay and costs Increased risk of cardiovascular complications Thromboembolic events Increased risk of Post procedural Bleeding Class/type of medication anticoagulant drugs antiplatelet agents Patient comorbidities Factors influencing decision Indication for procedure elective urgent/emergency Hold Continue Considerations: Risk of thromboembolism vs Risk inherent in the procedure TRILOGY Type of procedure high risk vs low risk Patient wishes decision must include patient in high risk cases
13 High Risk Patients ACS or STEMI h/o multi vessel PCI Drug eluting stents 12 months Bare metal coronary stents without ACS 1 month with history of ACS, 12 months prior history of stent thrombosis diffuse coronary artery disease renal failure h/o venous thromboembolism (VTE)/PE mechanical heart valves (but not bio prosthetic valves, which are low risk) Atrial Fibrillation with prior stroke/elderly Class/Type Drug Duration of Action Vitamin K antagonist Warfarin (Coumadin) 5 days Heparin & derivatives Direct Factor Xa inhibitor (oral) Direct Thrombin inhibitor Antithrombotic Drugs Unfractionated Heparin LMWHs Enoxeparin (Lovenox) Dalteparin (Fragmin) Fondaparinux (Arixtra) Rivaroxiban (Xarelto) Apixaban (Eliquis) Edoxaban (Savaysa) Oral: Dabigatran (Pradaxa) IV: Bivalirudin IV 2-6 h SQ h 24 h h 1-4 days* (*depends on egfr) 1-6 days* (*depends on egfr) 2-3 hours ASGE Standards of Practice Committee Gastrointest Endosc. 216 Jan;83(1):3 16. Management of DAPT in Elective Cases Management of Antithrombotics in Elective Cases DAPT Aspirin ADP blockers If patient has recently placed coronary stent and/or ACS Low risk procedures High risk procedures Continue Discontinue x 5-7 days prior or switch to bridge therapy Defer procedure until minimum DAPT completed Any short-term anticoagulation therapy Warfarin and NOACs High thrombosis risk Low thrombosis risk Defer procedure High risk procedure High risk procedure Low risk procedure Bridge therapy Stop for prescribed period Continue
14 DAPT in Emergency Procedures Anticothrombotics in Emergency Procedures INR <2.5 Do not delay procedure Emergency Procedures Life threatening bleeding High thrombosis risk patients Withhold after discussion with cardiologist Stop only after consultation with prescribing physician Bleeding or Emergency Surgery NOACs INR>2.5 4-Factor PCC + Vit K *ACCP recommended Fresh Frozen Plasma Antidotes After hemostasis achieved Start UFH for rapid onset Re-initiate previous medication Resumption of Therapy Warfarin should generally be resumed: hours after surgery Unless substantial risk of delayed bleeding or reoperation anticipated NOACs should generally be resumed: hours after a minor procedure hours after major surgery Bridging Therapy: (UFH or LMWH in high risk patients) NOAC should be resumed 1 hr before UFH infusion is discontinued or 1 12 hours after the last scheduled dose of LMWH Am J Health-Syst Pharm. 213; 7 (Suppl1):S3-11. J Cardivasc Electrophysiol. 211(8): N Engl J Med 213;368:
Asif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationChanging Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events
Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events Deepak L. Bhatt, MD, MPH Executive Director Interventional Cardiovascular Programs Brigham and Women s Hospital
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationDoes COMPASS Change Practice?
Does COMPASS Change Practice? C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division Chairman, PERFUSE Study Group Founder,
More informationState of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
More informationNAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING
NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationΠροβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα
Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More informationDISCLOSURE. What I am Talking About. Rational Use of Antiplatelet Agents. Aspirin. Tom DeLoughery, MD MACP FAWM
Rational Use of Antiplatelet Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University What I am Talking About 1. Current
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationRobert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences
Managing Atrial Fibrillation and ACS/PCI Applying New Evidence to Clinical Practice Dual Anti-Thrombotic Therapy in Acute Coronary Syndromes (ACS) and Afib + PCI/ACS Patients Robert C. Welsh, MD, FRCPC
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationDr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationAntiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center
Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationTriple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationAntiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants
Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants S. Hinan Ahmed, MD Anti-platelet Therapy: Simple Answer Bare metal stent
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationAnticoagulants and antiplatelet therapy in the older patient: Choosing wisely
Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific
More informationUPDATES FROM THE 2018 ANTIPLATELET GUIDELINES
UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationNews Release. For UK Media
News Release For UK Media Bayer plc 400 South Oak Way Reading RG2 6AD www.bayer.co.uk Bayer s Xarelto (rivaroxaban) in combination with single antiplatelet therapy receives positive CHMP opinion for treatment
More informationP 2 Y 12 Receptor Inhibitors
P 2 Y 12 Receptor Inhibitors Clopidogrel, Prasugrel and Ticagrelor Which Drug and for Whom? Cheol Whan Lee, MD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationAbbreviated Class Update: Anticoagulants, oral and parenteral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationDOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands
DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands RECENT DEVELOPMENTS Better anti-platelet agents: Prasugrel and Ticagrelor to replace
More informationAntiplatelet in diabetics: strong but incomplete umbrella
Antiplatelet in diabetics: strong but incomplete umbrella Seung-Whan Lee, MD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Global Projections for the Number
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationSecondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationThe Great debate: thrombocardiology post-compass
The Great debate: thrombocardiology post-compass Anticoagulation should replace antiplatelets in CAD prevention - CON Jean-Philippe COLLET Jean-philippe.collet@psl.aphp.fr Sorbonne Université_Action Study
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationComplicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital
Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More information